It also again demonstrates the market value of any treatment that even slows down the progress of Alzheimer's disease. Biogen and Eisai are probably going to lose over 20 billion in market cap today because of the news.
Sooner or later some of that value is going to come here. We have the phase 2 data already that shows what the phase 2b data is probably going to look like.
News 
Market Data 
Discover 
